MA51647A - Compositions et méthodes pour le traitement de la dermatite atopique et la sélection du traitement - Google Patents

Compositions et méthodes pour le traitement de la dermatite atopique et la sélection du traitement

Info

Publication number
MA51647A
MA51647A MA051647A MA51647A MA51647A MA 51647 A MA51647 A MA 51647A MA 051647 A MA051647 A MA 051647A MA 51647 A MA51647 A MA 51647A MA 51647 A MA51647 A MA 51647A
Authority
MA
Morocco
Prior art keywords
treatment
compositions
methods
atopic dermatitis
selection
Prior art date
Application number
MA051647A
Other languages
English (en)
Inventor
Michael D Howell
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MA51647A publication Critical patent/MA51647A/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/202—Dermatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MA051647A 2017-08-16 2018-08-15 Compositions et méthodes pour le traitement de la dermatite atopique et la sélection du traitement MA51647A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762546210P 2017-08-16 2017-08-16

Publications (1)

Publication Number Publication Date
MA51647A true MA51647A (fr) 2020-06-24

Family

ID=63686016

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051647A MA51647A (fr) 2017-08-16 2018-08-15 Compositions et méthodes pour le traitement de la dermatite atopique et la sélection du traitement

Country Status (12)

Country Link
US (1) US20210148910A1 (fr)
EP (1) EP3669004A1 (fr)
JP (1) JP2020531439A (fr)
KR (1) KR20200040803A (fr)
CN (1) CN110997939A (fr)
AU (1) AU2018318435A1 (fr)
CA (1) CA3071783A1 (fr)
EA (1) EA202090427A1 (fr)
IL (1) IL272646A (fr)
MA (1) MA51647A (fr)
SG (1) SG11202001068YA (fr)
WO (1) WO2019035005A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230073888A1 (en) * 2020-02-13 2023-03-09 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
WO2022117079A1 (fr) * 2020-12-03 2022-06-09 江苏恒瑞医药股份有限公司 Anticorps pouvant se lier à la lymphopoïétine stromale thymique et son utilisation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
SE462454B (sv) 1988-11-10 1990-06-25 Pharmacia Ab Maetyta foer anvaendning i biosensorer
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
WO1999051773A1 (fr) 1998-04-03 1999-10-14 Phylos, Inc. Systemes de proteines adressables
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
WO2000056934A1 (fr) 1999-03-24 2000-09-28 Packard Bioscience Company Reseaux matriciels poreux et continus
EP1212452B1 (fr) 1999-08-27 2013-07-17 Bristol-Myers Squibb Company Methodes de codage et de tri de proteines traduites in vitro
GB2384239A (en) 2001-12-05 2003-07-23 Sense Proteomic Ltd Arrays of protein variants
CN101292032A (zh) * 2005-10-21 2008-10-22 株式会社芳珂 特应性皮炎标记物及其利用技术
CN101370831B (zh) * 2006-01-13 2013-06-19 Irm责任有限公司 用于治疗过敏性疾病的针对胸腺基质淋巴细胞生成素受体的抗体
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
EP2773774A4 (fr) * 2011-11-03 2015-06-10 Merck Sharp & Dohme Biomarqueurs pour le traitement de tslp
US9790506B2 (en) * 2013-10-02 2017-10-17 The Regents Of The University Of California Diagnostic and screening methods for atopic dermatitis

Also Published As

Publication number Publication date
CA3071783A1 (fr) 2019-02-21
IL272646A (en) 2020-03-31
CN110997939A (zh) 2020-04-10
EA202090427A1 (ru) 2020-06-08
SG11202001068YA (en) 2020-03-30
KR20200040803A (ko) 2020-04-20
JP2020531439A (ja) 2020-11-05
US20210148910A1 (en) 2021-05-20
AU2018318435A1 (en) 2020-04-02
WO2019035005A1 (fr) 2019-02-21
EP3669004A1 (fr) 2020-06-24

Similar Documents

Publication Publication Date Title
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
MA46954A (fr) Méthodes de traitement d'états inflammatoires
MA47501A (fr) Dérivé de di-nucléotides cycliques pour le traitement du cancer
MA41028A (fr) Méthodes et formulations pour le traitement de pathologies oculaires vasculaires
MA49144A (fr) Polythérapies pour le traitement du cancer
MA43283A (fr) Procédés et compositions pour le traitement du cancer
MA52371A (fr) Méthodes de traitement d'infections dues aux coronaviridae
MA42135A (fr) Méthodes et trousses pour traiter la dépression
MA41119A (fr) Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
MA41449A (fr) Polythérapies pour le traitement de cancers
MA45675A (fr) Méthodes et compositions permettant le traitement du cancer
FR24C1017I1 (fr) Utilisations d'antagonistes d'il-13 pour le traitement de la dermatite atopique
MA42450A (fr) Méthodes de traitement de la stéatose hépatique non alcoolique et/ou de la lipodystrophie
MA47719A (fr) Esketamine pour le traitement de la dépression
MA41299A (fr) Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
MA48637A (fr) Polythérapies pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
HK1247789A1 (zh) 用於治療水腫的組合物和方法
MA43230A (fr) Méthodes et compositions pour le traitement d'une épidermolyse bulleuse
FR3022139B1 (fr) Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee
MA41629A (fr) Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
MA40687A (fr) Méthodes et compositions de traitement de malformation vasculaire
MA51647A (fr) Compositions et méthodes pour le traitement de la dermatite atopique et la sélection du traitement
HK1254242A1 (zh) 用於治療炎性腸病和異位性皮炎的組合物